Skip to main content
. 2023 Jun 14;8(25):22603–22612. doi: 10.1021/acsomega.3c01110

Figure 3.

Figure 3

Dose–response curves of kinase inhibitors tested against PLpro. (A) Olmutinib, IC50 0.54 ± 0.04 μM, (B) Dacomitinib, IC50 3.30 ± 0.06 μM, (C) Crizotinib 3.80 ± 0.04 μM, and (D) Bosutinib IC50 4.20 ± 0.28 μM. All experiments were performed in triplicate, and all data are expressed as the mean ± standard deviation.